ArticleCardiovascular and interventional radiology2026
Lipiodol-Mediated Dose Enhancement in Radiation Therapy: A Phantom and In Vitro Study in Hepatocellular Carcinoma.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess Lipiodol-mediated photon dose perturbation and biological effects using complementary kilovoltage and megavoltage irradiation geometries relevant to hepatocellular carcinoma. MATERIALS AND
methodsPhantom dosimetry used containers filled with lipiodol-oil mixtures (0-100%) embedded in a water phantom with radiochromic film to quantify concentration-dependent enhancement under 6-MV beam. HepG2 human hepatoma cells were irradiated at 0-6 Gy using 160-kVp (photoelectric effect dominant) with lipiodol or water placed beneath the cell monolayer to isolate backscatter; γH2AX foci indicating DNA damage were quantified shortly after irradiation. For megavoltage testing, a 6-MV (Compton scattering dominant) Lipiodol-rich "sandwich" geometry (Lipiodol above and below the cell monolayer) was used; apoptosis was quantified at 96 h using NucView/NucSpot (apoptotic fraction), and results are reported descriptively.
resultsFilm dosimetry demonstrated increasing enhancement with Lipiodol concentration, spatially localized to the Lipiodol region, with a maximum localized increase of 57.1% at 100% Lipiodol versus water. In the 160-kVp backscatter model, higher γH2AX foci were observed at 4 and 6 Gy in Lipiodol versus control. In the 6-MV sandwich model, cell-plane film confirmed an 11.5% higher delivered dose at 2 Gy with Lipiodol and apoptotic fraction was 1.36-5.79-fold higher across 2-6 Gy compared to the control.
conclusionLipiodol measurably intensified local photon dose and was associated with greater DNA damage and apoptosis in phantom and HepG2 cell models. These findings provide mechanistic support for combining radiotherapy with Lipiodol-based transarterial treatments and highlight the need for further in vivo validation and clinical studies.
Indexed as
Identifiers
41692835What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.